Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AstraZeneca cuts early-phase prostate cancer pipeline
AstraZeneca has punted a pair of early-phase prostate cancer programs as part of its quarterly pipeline clear out.
Nick Paul Taylor
Oct 30, 2026 5:03am
ESMO: AZ exec insists ph. 3 ADC data ‘robust’ despite PFS miss
Oct 25, 2026 11:30am
AstraZeneca taps Oracle to improve recruitment for trials
Oct 20, 2026 2:36am
AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal
Oct 15, 2026 6:00am
AZ hopes for ‘amazing things’ from Kendall Square R&D center
Oct 6, 2026 5:30am
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
Sep 29, 2026 3:07am
